Compass Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMPX research report →
Range $4 – $6
Price Chart
About the company
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions.
- CEO
- Thomas J. Schuetz
- IPO
- 2021
- Employees
- 39
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on CMPX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $178.47M
- P/E
- -2.39
- Fwd P/E
- 14.34
- PEG
- -0.27
- P/S
- 0.00
- P/B
- 1.11
- EV/EBITDA
- -2.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.71%
- ROIC
- -46.15%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-1,472,000-273.2%
- Op Income
- $-72,839,000
- Net Income
- $-66,489,000-34.7%
- EPS
- $-0.42-16.7%
- OCF Growth
- -9.6%
- FCF Growth
- -9.5%
- 52W High
- $6.88
- 52W Low
- $0.83
- 50D MA
- $1.95
- 200D MA
- $3.61
- Beta
- 0.84
- RSI (14)
- 25
- Avg Volume
- 4.02M
No earnings-call transcripts are available for CMPX yet.
- Free Float
- 68.1%
- Shares Outstanding
- 180.09M
- Float Shares
- 122.69M
of shares held by institutions
209 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tang Capital Management LLC | 17.99M | ▲ 1.20M |
| Orbimed Advisors LLC | 15.22M | 0 |
| Suvretta Capital Management, LLC | 14.10M | ▼ 206.22K |
| Blackrock, Inc. | 11.28M | ▲ 1.78M |
| State Street Corp | 9.95M | ▲ 3.26M |
| Vanguard Group Inc | 8.05M | ▲ 985.58K |
| Enavate Sciences Gp, LLC | 7.79M | 0 |
| Vivo Capital, LLC | 7.76M | ▼ 1.79M |
| Vanguard Capital Management LLC | 6.12M | ▲ 81.61K |
| Palo Alto Investors LP | 5.83M | ▲ 4.32M |
| Millennium Management LLC | 4.71M | ▲ 3.87M |
| Geode Capital Management, LLC | 3.82M | ▲ 249.42K |
Held by 131 ETFs
Biggest fund positions in CMPX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Lerner Neil | buy | 20,000 |
| Sep 24, 26 | Lerner Neil | buy | 2,500 |
| Apr 29, 26 | Lerner Neil | buy | 15,000 |
| Apr 29, 26 | Anderman Jonathan | buy | 25,000 |
| Apr 29, 26 | Anderman Jonathan | other | 25,000 |
| Apr 29, 26 | Lerner Neil | other | 15,000 |
| Feb 8, 26 | Schuetz Thomas J. | other | 36,687 |
| Jan 9, 26 | Schuetz Thomas J. | other | 46,777 |
| Jan 2, 26 | Shin Barry | other | 670,000 |
| Jan 2, 26 | Shin Barry | other | 125,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CMPX coverage
Recent articles, reports, and earnings notes.
No research on CMPX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CMPX report →Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity
seekingalpha.com · Sep 23
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
benzinga.com · Sep 22
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
globenewswire.com · Sep 22
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
globenewswire.com · Aug 6
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
globenewswire.com · Jul 17
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity
seekingalpha.com · Jul 15
Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com · Jun 9
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
marketbeat.com · Jun 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.